Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:517239.
doi: 10.1155/2013/517239. Epub 2013 Jul 28.

Serum anti-müllerian hormone levels in patients with epithelial ovarian cancer

Pawel Walentowicz  1 , Pawel Sadlecki, Magdalena Krintus, Grazyna Sypniewska, Aneta Mankowska-Cyl, Marek Grabiec, Malgorzata Walentowicz-Sadlecka
Affiliations

Serum anti-müllerian hormone levels in patients with epithelial ovarian cancer

Pawel Walentowicz et al. Int J Endocrinol. 2013.

Abstract

Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45-79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0-0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15-0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading (P > 0.05). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival curves in relation to AMH levels.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer Journal for Clinicians. 2012;62(1):10–29. - PubMed
    1. Park Y, Lee J-H, Hong DJ, Lee EY, Kim H-S. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clinical Biochemistry. 2011;44(10-11):884–888. - PubMed
    1. Walentowicz-Sadlecka M, Grabiec M, Sadlecki P, et al. Sypniewska G. 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clinical Biochemistry. 2012;45:1568–1572. - PubMed
    1. La Marca A, Stabile G, Carducci Artenisio A, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Human Reproduction. 2006;21(12):3103–3107. - PubMed
    1. Alebić MŠ, Stojanović N, Zuvić-Butorac M. The IVF outcome counseling based on the model combining DHEAS and age in patients with low AMH prior to the first cycle of GnRH antagonist protocol of ovarian stimulation. International Journal of Endocrinology. 2013;2013637919 - PMC - PubMed

LinkOut - more resources